Objectives
To investigate the association between early pregnancy ondansetron use and risk of cardiac defects in a national level dataset.
Methods
Maternal and child medical claims data were obtained from Truven Health Analytics for all live births from 2000 to 2014. Logistic regression was used to measure the association between early pregnancy exposure to ondansetron and risk of specific structural defects in offspring.
Results
Our dataset contained 1,149,145 live births from 1,004,175 mothers. Of these, 76,330 infants were exposed to ondansetron in-utero during the first trimester (5,557 exposed exclusively in medical settings), and 61,830 infants were diagnosed with structural defects. First trimester exposure to ondansetron in a medical setting was associated with increased risk of structural (OR: 1.34 95% CI: 1.23-1.47), cardiac (OR: 1.52 95% CI: 1.35-1.70) and orofacial cleft defects (OR: 1.32 95% CI: 0.76-2.28) in offspring compared to women with no antiemetic exposure during pregnancy. Risk was highly elevated for atrioventricular septal defects (OR: 2.68 95% CI: 1.61-4.47) and diaphragmatic hernia (OR: 2.49 95% CI: 1.18-5.25).
Conclusions
This study in a large, US population demonstrates a statistically significant association between early pregnancy ondansetron and risk of structural birth defects in offspring. Our analysis addresses limitations of prior studies including limited power, exposure misclassification, and generalizability to the US population.
Article info
Identification
Copyright
© 2018 Published by Elsevier Inc.
User license
Elsevier user license | How you can reuse 
Elsevier's open access license policy
Elsevier user license
Permitted
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
Not Permitted
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy
